INGN

Inogen is a classic broken-IPO deep-value setup with a real margin of safety but no earnings power yet. The balance sheet is the anchor: $104M cash against essentially no debt (long-term + current debt total ~$0.6M) and $192M equity, giving liabilities/equity of just 0.55x. At a $180M market cap, roughly $104M — about $3.82 of the $6.60 share price — is net cash, so the operating business trades for well under 0.3x its $295M of revenue. That's cheap for a company whose revenue has climbed back from the $252M FY2023 trough to $295M (+5.9%), and whose net loss has narrowed three years running (-$102M → -$35.9M → -$22.7M). The $27.2M received from Yuwell also signals a strategic partner willing to fund the story, and management states current cash plus securities should cover operations for at least the next 12 months.

But the reason this is a hold rather than a buy is that the fundamentals still don't work. The company is unprofitable at every line — operating margin -10.2%, net margin -7.7%, ROE -11.8% — and gross profit was actually flat to down (-0.3%) despite revenue growth, so the improvement is coming from cost cuts (including a 10% cut to R&D) rather than operating leverage. Most importantly, operating cash flow swung from +$5.9M in 2024 to -$11.2M in 2025 (down ~290%), and the accumulated deficit widened to -$176M. A turnaround that is still burning cash after years of losses is not yet de-risked.